Spectrum’s Fusilev Faces No Generic Threat, Shrotriya Says

Spectrum Pharmaceuticals Inc.’s colon-cancer drug Fusilev won’t face generic competition until the shot’s patent protection expires in eight years, Chief Executive Officer Rajesh Shrotriya said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.